Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | PGR | P06401 | 2/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | SHBG | P04278 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11814284 | 0.88 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL7519660 | 0.88 | HIF1A (0.75) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL29064801 | 0.87 | HIF1A (0.73) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL16020569 | 0.86 | HIF1A (0.78) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL10733115 | 0.86 | HIF1A (0.69) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL8071547 | 0.86 | HIF1A (0.77) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL7614974 | 0.86 | HIF1A (0.77) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL1573841 | 0.85 | HIF1A (0.63) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL9437393 | 0.85 | HIF1A (0.75) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 | |
| SCHEMBL8920369 | 0.85 | HIF1A (0.67) | HIF1ALMNANR3C1SMN1; SMN2NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140170768-A1 | METHOD FOR MONITORING AND ASSESSING PITUITARY FUNCTION | I-CALQ LLC | 2014-06-19 | — | — | US | claimed |
| EP-2532350-A1 | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome | Laboratoire HRA Pharma (FR) | 2012-12-12 | — | — | EP | claimed |
| US-20100261693-A1 | METHOD FOR TREATING CUSHING'S SYNDROME | LABORATOIRE HRA PHARMA (FR) | 2010-10-14 | — | — | US | claimed |
| EP-2211845-A2 | GLUCOCORTICOID RECEPTOR ANTAGONISTS SUCH AS MIFEPRISTONE FOR TREATING CUSHING'S SYNDROME | Laboratoire HRA Pharma (FR) | 2010-08-04 | — | — | EP | claimed |
| WO-2009050136-A2 | GLUCOCORTICOID RECEPTOR ANTAGONISTS SUCH AS MIFEPRISTONE FOR TREATING CUSHING' S SYNDROME | LABORATOIRE HRA PHARMA (FR) | 2009-04-23 | — | — | WO | claimed |
| EP-1424998-A4 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | UNIV PENNSYLVANIA (US) | 2005-11-23 | — | — | EP | claimed |
| US-20050069577-A1 | Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies | TRUSTEES OF UNIVERSITY OF PENNSYLVANIA | 2005-03-31 | — | — | US | claimed |
| EP-1424998-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | The Trustees of The University of Pennsylvania (US) | 2004-06-09 | — | — | EP | claimed |
| WO-2003015757-A1 | SYNTHESIS AND USE OF REAGENTS FOR IMPROVED DNA LIPOFECTION AND/OR SLOW RELEASE PRODRUG AND DRUG THERAPIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-02-27 | — | — | WO | claimed |
| US-20020065259-A1 | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) | 2002-05-30 | — | — | US | claimed |
| WO-2002017930-A2 | GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD-BRAIN BARRIER PERMEABILITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-03-07 | — | — | WO | claimed |
| US-4296206-A | Irreversible anti-glucocorticoids | UNITED STATES OF AMERICA (US) | 1981-10-20 | — | — | US | claimed |
| CN-109071537-B | Use of glucocorticoid receptor modulators for potentiating checkpoint inhibitors | 科赛普特治疗学股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240156835-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | CORCEPT THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11969435-B2 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | CORCEPT THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3265127-B1 | MIFEPRISTONE AND OCTREOTIDE FOR USE IN THE TREATMENT OF CUSHING'S SYNDROME IN A PATIENT HAVING AN ADRENOCORTICOTROPIC HORMONE (ACTH)-SECRETING PANCREATIC NEUROENDOCRINE TUMOR | CORCEPT THERAPEUTICS INC (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-1999059596-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEMENTIA | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999017779-A1 | METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH GLUCOCORTICOID RELATED DYSFUNCTION | THE BOARD OF TRUSTEES OF LELAND STANFORD JR. UNIVERSITY (US) | 1999-04-15 | — | — | WO | disclosed |
| US-4296206-A | Irreversible anti-glucocorticoids | UNITED STATES OF AMERICA (US) | 1981-10-20 | — | — | US | disclosed |
| US-4296206-A | Irreversible anti-glucocorticoids | UNITED STATES OF AMERICA (US) | 1981-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261693-A1 | METHOD FOR TREATING CUSHING'S SYNDROME | MC2R, CRH, CRHR2 | HIF1A 3874/4885LMNA 3604/4885NR3C1 9/4885 |
| US-11969435-B2 | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors | NR3C1, NR3C2, CYP3A5 | HIF1A 3036/4885LMNA 4861/4885NR3C1 1/4885 |
| US-20240156835-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS IN COMBINATION WITH GLUCOCORTICOIDS TO TREAT ADRENAL INSUFFICIENCY | NR3C2, MC2R, NR3C1 | HIF1A 3026/4885LMNA 3702/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.